591 related articles for article (PubMed ID: 30653855)
1. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
2. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
3. Methylphenidate for children and adolescents with autism spectrum disorder.
Sturman N; Deckx L; van Driel ML
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
[TBL] [Abstract][Full Text] [Related]
4. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
[TBL] [Abstract][Full Text] [Related]
5. No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder.
Harfterkamp M; van der Meer D; van der Loo-Neus G; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2015 May; 25(4):372-5. PubMed ID: 25919900
[No Abstract] [Full Text] [Related]
6. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
7. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D; Leach MJ; Perez Algorta G
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng JY; Chen RY; Ko JS; Ng EM
Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
[TBL] [Abstract][Full Text] [Related]
11. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine for treating ADHD symptoms in autism: a systematic review.
Ghanizadeh A
J Atten Disord; 2013 Nov; 17(8):635-40. PubMed ID: 22544388
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
Cunill R; Castells X; Tobias A; Capellà D
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
McBurnett K; Clemow D; Williams D; Villodas M; Wietecha L; Barkley R
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):38-42. PubMed ID: 27845858
[TBL] [Abstract][Full Text] [Related]
15. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
Liu Q; Zhang H; Fang Q; Qin L
J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials.
Ravishankar V; Chowdappa SV; Benegal V; Muralidharan K
Asian J Psychiatr; 2016 Dec; 24():53-58. PubMed ID: 27931908
[TBL] [Abstract][Full Text] [Related]
18. Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
Shaywitz S; Shaywitz B; Wietecha L; Wigal S; McBurnett K; Williams D; Kronenberger WG; Hooper SR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):19-28. PubMed ID: 27410907
[TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
